natgillin/translations-raw huggingface dataset:
The CHMP noted the detailed analyses of the authorised texts and the wording proposed and in summary, the CHMP considered that the use of Augmentin should be avoided during pregnancy, unless considered essential by the physician and that amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge. 
CHMP je na splošno menil, da se je treba uporabi zdravila Augmentin med nosečnostjo izogniti, razen če zdravnik meni, da je to nujno potrebno, ter da se lahko kombinacija amoksicilin/klavulanska kislina uporabi med dojenjem šele, ko pristojni zdravnik ovrednoti razmerje med koristmi in tveganji.
The clinical studies in CAP and AECB further confirm the efficacy of Augmentin SR in treating infections due to beta-lactamase-producing H. influenzae and M. catarrhalis. 
Klinične študije izvenbolnišnično pridobljene pljučnice in akutnega poslabšanja kroničnega bronhitisa dodatno potrjujejo učinkovitost zdravila Augmentin SR pri zdravljenju okužb zaradi bakterij H. influenzae in M. catarrhalis, ki tvorijo beta laktamaze.
The MAH agreed to withdraw the indication SSTI and tonsillopharyngitis, as well as the initially proposed indication UTI. 
Imetniki dovoljenj za promet z zdravilom so se strinjali z umikom indikacije okužb kože in mehkih tkiv ter tonzilofaringitisa ter v začetku predlagane indikacije okužb sečil.
The standard dose is TID and the CHMP restricted the lower dose to SSTI and non-severe sinusitis. 
Standardni odmerek je jemanje trikrat dnevno, manjši odmerek pa je CHMP omejil na okužbe kože in mehkih tkiv ter sinusitis, ki ni resen.
The CHMP agreed with the main conclusion drawn by the MAH, however new studies comparing the efficacy of the 4:1 and 8:1 ratio showed a clear inferiority of the 4:1 ratio, when bacteria with higher MIC values were the causative agents. 
CHMP se je strinjal z glavnimi zaključki imetnikov dovoljenj za promet z zdravilom, vendar so nove študije primerjave učinkovitosti razmerja 4:1 in 8:1 pokazale očitno manjvrednost razmerja 4:1 v primerih, ko so bili povzročitelji bakterije z višjimi vrednostmi MIC. Za indikacije, ki so bile obravnavane v primeru razmerja 2:1, je edina razlika povečan odmerek amoksicilina 0,5 g trikrat dnevno (odrasli).
Finally, the MAH discussed the PK/PD of the 8:1 ratio, stating that the steady-state mean T>MIC values predict that this formulation given TID achieves maximum eradication against S. pneumoniae strains with amoxicillin or amoxicillin/clavulanic acid MICs of ≤2g/mL and is to have some efficacy against strains with MICs of 4g/mL. 
Na koncu so imetniki dovoljenj za promet z zdravilom razpravljali o farmakokinetiki/farmakodinamiki razmerja 8:1 ter navedli, da povprečne ravnovesne vrednosti T>MIC napovedujejo, da bo ta formulacija pri dajanju trikrat dnevno dosegla največjo eradikacijo sevov S. pneumoniae, ki imajo MIC amoksicilina ali kombinacije amoksicilin/klavulanska kislina ≤2 μg/mL, nekoliko pa bo učinkovita proti sevom z vrednostmi MIC 4 μg/mL.
Augmentin has the appropriate PK/PD that would predict clinical efficacy against Gram-positive and many Gramnegative pathogens including anaerobic pathogens, and penetrates well into the peritoneum. 
Zdravilo Augmentin ima primerno farmakokinetiko/farmakodinamiko, ki napoveduje klinično učinkovitost proti grampozitivnim in številnim gramnegativnim patogenom, vključno z anaerobnimi povzročitelji, ter dobro prehaja v peritonej.
• Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. 
• okužbe kože in mehkih tkiv, zlasti celulitis, ugrizi živali in hudi zobni abscesi s celulitisom, ki se širi.
• Community acquired pneumonia 
• izvenbolnišnično pridobljena pljučnica
As Augmentin SR was developed, clinically tested and approved for treatment of PRSP, a statement was retained to advise prescribers that these formulations are appropriate for use in treating infections that are caused, or suspected to be caused, by penicillin-resistant S. pneumoniae. 
Ker je bilo zdravilo Augmentin ES razvito, klinično preskušeno in odobreno za zdravljenje proti penicilinu odpornega S. pneumoniae, se ohrani izjava kot nasvet zdravnikom, ki zdravilo predpisujejo, da so te formulacije primerne za zdravljenje okužb, ki jo povzroča ali obstaja sum, da jo povzroča proti penicilinu odporni S. pneumoniae.
• Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis 
• okužbe kože in mehkih tkiv, zlasti celulitis, ugrizi živali in hudi zobni abscesi s celulitisom, ki se širi
Finally, the paediatric posology for the 5:1 ratio was revised as IV doses of clavulanic acid greater than 5 mg/kg are not recommended and Section 4.2 already contains texts advocating the use of different strengths where higher amoxicillin doses are needed. 
odmerki klavulanske kisline, ki so večji od 5 mg/kg, ne priporočajo in poglavje 4.2 že vsebuje besedila, ki zagovarjajo uporabo različnih jakosti v primerih, ko so potrebni večji odmerki amoksicilina.
The MAH acknowledged that the Phase III programme studied only AOM and that the other indications including CAP, ABS and SSTI were extrapolated based on PK/PD principles, as results from AOM studies have shown that the PK/PD concept is predictive for clinical outcome. 
Imetniki dovoljenj za promet z zdravilom so priznali, da so v programu III. faze preučili samo akutno vnetje srednjega ušesa ter da so druge indikacije, vključno z izvenbolnišnično pridobljeno pljučnico, akutnim bakterijskim sinusitisom ter okužbami kože in mehkih tkiv, ekstrapolirali na osnovi principov farmakokinetike/farmakodinamike, saj so rezultati študij akutnega vnetje srednjega ušesa pokazali, da koncept farmakokinetike/farmakodinamike napoveduje klinični izid.
Amoxicillin, like other beta-lactam antibiotics, is largely excreted renally and is not metabolised by CYP450 enzymes; clavulanic acid is partially metabolised by the liver and mostly excreted unchanged in the urine. 
Amoksicilin se tako kot drugi betalaktamski antibiotiki večinoma izloča skozi ledvice in ga ne presnavljajo encimi CYP450.
The MAH stated the currently approved indications and discussed in particular the indications in genito-urinary tract, abdominal infections, respiratory tract infections and skin and soft tissue Infections (SSTIs), citing numerous clinical studies and guidelines recommending the use of the 4:1 ratio. 
Imetniki dovoljenj za promet z zdravilom so navedli trenutno odobrene indikacije in podrobno razpravljali o indikacijah v zvezi z okužbami spolovil, sečil, trebuha, dihal, kože in mehkih tkiv, pri čemer so se sklicevali na številne klinične študije in smernice, ki priporočajo uporabo razmerja 4:1.
To date the 4:1 ratio has been approved widely in Europe and the approval in 1984 of the TID dosage was supported by clinical studies in paediatric and adult patients. 
Odobritev odmerjanja trikrat dnevno leta 1984 je bilo podprto s kliničnimi študijami pri otrocih in odraslih bolnikih.
The CHMP agreed to the MAH proposal. 
CHMP se je strinjal s predlogom imetnikov dovoljenj za promet.
The following statements were agreed for the harmonised SPC to address this issue: 
Odbor se je strinjal o naslednjih izjavah za usklajene povzetke glavnih značilnosti zdravila, v katerih se obravnava ta težava:
The interactions apply to all Augmentin ratios. 
Interakcije se nanašajo na vsa razmerja zdravila Augmentin.
There is no consensus on the appropriate treatment duration, as other factors such as the extent of infection, type of pathogen, clinical response, and presence of underlying risk factors are important considerations but the current SPCs only stipulate that patients on extended therapy beyond 14 days should be closely monitored. 
Soglasja o primernem trajanju zdravljenja ni, saj so pomembni drugi dejavniki, kot so obsežnost okužbe, vrsta patogena, klinični odziv in prisotnost obstoječih dejavnikov tveganja.
All EU approvals have been obtained via National registration; leading to a number of differences in the PI, particularly in the Indication and Posology sections and a referral was therefore triggered in order to resolve the divergences amongst the nationally authorised SPCs and thus to harmonise the SPCs across the EU. 
Vse odobritve v EU so dosežene z nacionalno registracijo; kar je povzročilo številne razlike v informacijah o zdravilu, zlasti v poglavjih Indikacije in Odmerjanje.
Following the launch of Augmentin TID and BID regimens, resistance to penicillins in respiratory tract pathogens has generally increased significantly. 
Po začetku trženja zdravil Augmentin z režimoma trikrat dnevno in dvakrat dnevno se je na splošno odpornost proti penicilinom pri povzročiteljih okužb dihal bistveno povečala.
The ADME properties of amoxicillin and clavulanic acid, alone and in combination, were also summarised. 
Povzete so bile tudi lastnosti absorpcije, porazdelitve, presnove in izločanja (ADME) amoksicilina in klavulanske kisline posamezno in v kombinaciji.
Augmentin is considered suitable for the treatment of osteomyelitis as it has appropriate PK/PD properties, provides efficacy against MSSA, Gram-negative (susceptible isolates) and also anaerobic cover for polymicrobial infections. 
Augmentin štejemo kot primernega za zdravljenje osteomielitisa in ima primerne farmakokinetične/farmokodinamične lastnosti in učinkovitost proti Staphylococcus aureus, občutljivemu za meticilin (MSSA), in gramnegativnim povzročiteljem (občutljivi izolati) ter pokriva tudi anaerobne povzročitelje pri polimikrobnih okužbah.
The information provided for this section applies to all Augmentin ratios. 
Podatki, ki so navedeni v tem poglavju, se nanašajo na vsa razmerja zdravila Augmentin.
The MAH proposed the same indications for the 2:1, 4:1, 7:1 and 8:1 ratios and these are discussed in common. 
Imetniki dovoljenj za promet z zdravilom so predlagali enake indikacije za razmerja 2:1, 4:1, 7:1 in 8:1, zato se te skupine razmerij obravnavajo skupaj.
Dosing recommendations for Augmentin ES are supported by clinical safety and efficacy data in AOM. 
Priporočila za odmerjanje zdravila Augmentin ES podpirajo podatki o klinični varnosti in učinkovitosti pri akutnem vnetju srednjega ušesa.
In adults, the higher dosage is recommended for severe infections, including chronic and recurrent urinary tract infections and lower respiratory tract infections. 
Pri odraslih je večji odmerek priporočen za hude okužbe, vključno s kroničnimi in ponavljajočimi se okužbami sečil in spodnjih dihal.
Thus, the maximum daily dose of amoxicillin delivered with the 2:1 ratio is 750 mg. 
Zato je 750 mg največji dnevni odmerek amoksicilina, ki se vnese z razmerjem 2:1.
The MAH agreed to the withdrawal of the septicaemia indication from of all the oral and parental formulations SPCs. 
Imetniki dovoljenj za promet z zdravilom so se strinjali z umikom indikacije septikemija iz vseh peroralnih in parenteralnih formulacij povzetka glavnih značilnosti zdravila.
The MAH also listed a number of published studies and discussed other indications, such as skin and soft tissue infections (SSTI), bone and joint infections, abdominal infection, pelvic inflammatory disease, UTI and dental infections. 
Imetniki dovoljenj za promet z zdravilom so navedli številne objavljene študije in razpravljali o drugih indikacijah, kot so okužbe kože in mehkih tkiv, okužbe kosti in sklepov, abdominalne okužbe, medenične vnetne bolezni, okužbe sečil in dentalne okužbe.
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Augmentin and associated names (see Annex I). 
je CHMP priporočil dopolnitev dovoljenj za promet z zdravilom Augmentin in povezanih imen (glejte Dodatek I).
The MAH concluded that Augmentin therapy for osteomyelitis should be initially parenteral, followed by a switch to oral. 
da mora biti zdravljenje osteomielitisa z zdravilom Augmentin uvedeno kot parenteralno, čemur sledi prehod na peroralno obliko.
In children, the higher dosage is recommended for infections such as otitis media, sinusitis, lower respiratory tract infections and urinary tract infections. 
Pri otrocih je večji odmerek priporočen za okužbe, kot so okužba srednjega ušesa, sinusitis, okužbe spodnjih dihal in sečil.
The CHMP endorsed the MAH data and rationale, especially the polymicrobial nature of intra-abdominal infections and the recent use of Augmentin in controlled trials support the use of Augmentin for both initial empirical IV treatment and continued oral treatment after switch from IV treatment. 
Zlasti polimikrobna narava intraabdominalnih okužb in nedavna uporaba zdravila Augmentin v kontroliranih preskušanjih podpirajo uporabo tega zdravila za začetno empirično i.v.
The MAH updated the Augmentin SPCs in line with the CHMP's guidance on the development of antibacterial agents. 
Imetniki dovoljenj za promet z zdravilom so posodobili povzetke glavnih značilnosti zdravila v skladu s smernicami CHMP o razvoju protibakterijskih zdravil.
A full PIQ review was also conducted and the PL was revised accordingly. 
Opravljen je bil popoln pregled kakovosti informacij o zdravilu (PIQ) in skladno s tem je bilo popravljeno navodilo za uporabo.
The CHMP concluded that due to the lack of efficacy data, bridging from efficacy in AOM to ABS it not supported. 
CHMP je menil, da zaradi pomanjkanja podatkov o učinkovitosti, prenos iz učinkovitosti pri akutnem vnetju srednjega ušesa na učinkovitost pri akutnem bakterijskem sinusitisu ni podprt.
Therefore the following wording was adopted for all Augmentin IV formulations by the CHMP: 
Zato je CHMP sprejel naslednje besedilo za vse i.v.
The 8:1 Augmentin ratio was licensed in 1990, developed in response to concerns over the increasing prevalence of resistant S. pneumoniae strains in France, particularly amongst young children with acute otitis media. 
Razvito je bilo kot odziv na zadržke o povečanju pogostnosti odpornih sevov S. pneumoniae v Franciji, zlasti med majhnimi otroci z akutnim vnetjem srednjega ušesa.
In particular, data on renal impairment, crystalluria and overgrowth of fungal infections and acute generalised exanthematous pustulosis (AGEP) was reviewed and proposals for a harmonised wording were made. 
Zlasti so bili pregledani podatki o okvarjenem delovanju ledvic, kristaluriji, prerasti gliv in akutni generalizirani eksantemski pustulozi (AGEP).
During the evaluation, outstanding issues were identified, to be addressed by the MAH. 
Med vrednotenjem so bili ugotovljeni nerešeni zadržki, ki jih morajo rešiti imetniki dovoljenj za promet z zdravilom.
THERAPEUTIC INDICATIONS FOR AUGMENTIN 16:1 RATIO (ORAL - SR) 
TERAPEVTSKE INDIKACIJE ZA ZDRAVILO AUGMENTIN Z RAZMERJEM 16:1 (PERORALNO - SR)
Amoxicillin works by inhibiting the transpeptidase enzyme responsible for cross-linking peptidoglycan in the bacterial cell wall, weakening, the cell wall and making the cell swell and rupture. 
Amoksicilin deluje z zaviranjem encima transpeptidaze, ki je odgovoren za mrežno povezanost peptidoglikana v bakterijski celični steni.
However, because no supporting documentation was provided in support of indications other than AOM and CAP, the remaining indications should be deleted. 
Vendar je bila predložena samo dokumentacija v podporo indikacijam akutno vnetje srednjega ušesa in izvenbolnišnično pridobljena pljučnica, zato je treba ostale indikacije izbrisati.
Surgical prophylaxis with Augmentin IV should aim to protect the patient for the period of risk of infection. 
mora ščititi bolnika v obdobju tveganja okužbe.
Amoxicillin/clavulanic acid was originally developed in response to the need for an oral broad-spectrum antibiotic that covered β-lactamase-producing pathogens. 
Kombinacija amoksicilin/klavulanska kislina je bila sprva razvita kot odziv na potrebo po peroralnem širokospektralnem antibiotiku, ki bi pokril patogene, ki tvorijo laktamazo β. Peroralne formulacije zdravila Augmentin so bile po svetu na voljo od leta 1981, intravenske pa od leta 1984.
The CHMP recommended including the following in the harmonised SPC: 
CHMP je priporočil vključitev naslednjih besedil v usklajene povzetke glavnih značilnosti zdravila:
The MAH listed the currently approved indications and discussed data from clinical trials in paediatric patients and adults in the treatment of otitis media and UTIs, demonstrating the bioequivalence of the 8:1 adult regimen to the 8:1 paediatric regimen and the efficacy of the 8:1 ratio BID in adults; consequently this regimen has now become well established in France for the treatment of respiratory tract infections in adults, including CAP, AECB, acute bronchitis, AOM and sinusitis. 
Imetniki dovoljenj za promet z zdravilom so navedli trenutno odobrene indikacije in razpravljali o podatkih iz kliničnih preskušanj pri otrocih in odraslih bolnikih za zdravljenje srednjega ušesa in okužb sečil, ki dokazujejo biološko enakovrednost odraslega režima 8:1 z otroškim režimom 8:1 ter učinkovitost razmerja 8:1 dvakrat dnevno pri odraslih.
The MAH listed the currently approved indications and discussed respiratory tract infections (RTIs), AOM, community acquired pneumonia (CAP), tonsillo-pharyngitis and sinusitis, skin and soft tissue infections (SSTI) and urinary tract infections (UTI). 
Imetniki dovoljenj za promet z zdravilom so navedli trenutno odobrene indikacije in razpravljali o okužbah dihal, akutnem vnetju srednjega ušesa, izvenbolnišnično pridobljeni pljučnici, tonzilo-faringitisu in sinusitisu, okužbah kože in mehkih tkiv ter okužbah sečil.
This is further supported by several Guidance documents and the CHMP adopted the indication: “Intra-abdominal infections” for the IV Augmentin formulations. 
formulacije zdravila Augmentin sprejel indikacijo: “intraabdominalne okužbe”.
The major indications discussed for the 2:1 Augmentin ratio included genito-urinary tract infections, RTIs, and SSTIs. 
Poglavitne indikacije, obravnavane za zdravilo Augmentin v razmerju 2:1, so bile okužbe spolovil in sečil, okužbe dihal ter okužbe kože in mehkih tkiv.
The MAH provided a large body of data supporting the use of IV Augmentin, including studies and review articles confirming the efficacy of both IV and sequential IV/oral Augmentin therapy in the treatment of LRTIs. 
zdravila Augmentin, vključno s študijami in preglednimi članki, ki potrjujejo učinkovitost tako i.v.
The MAH provided a comprehensive summary of the key studies evaluated and further justifications and data to support the indication in CAP, ABS and acute exacerbations of chronic bronchitis (AECB). 
Pregledani podatki dokazujejo klinične koristne učinke formulacije SR, kar je znanstvena osnova za odobritev trenutnih nacionalnih licenc za Augmentin SR. Imetniki dovoljenj za promet z zdravilom so predložili obsežen povzetek ovrednotenih ključnih študij ter dodatne utemeljitve in podatke v podporo indikaciji izvenbolnišnično pridobljena pljučnica, akutni bakterijski sinusitis in akutno poslabšanje kroničnega bronhitisa.
The CHMP noted that tonsillitis/pharyngitis and uncomplicated sinusitis are often viral in origin, and when due to bacteria, the most common pathogen is S. pyogenes, which is always susceptible to penicillin, to be treated with amoxicillin alone or with penicillin. 
Klavulanska kislina ščiti amoksicilin pred inaktivacijo v primerih, ko so okužbe polimikrobne ali ko so prisotni nepatogeni organizmi, ki tvorijo laktamazo β. CHMP je izpostavil, da so tonzilitis/faringitis ter nezapleteni sinusitis pogosto virusnega vzroka, kadar pa so vzrok zanje bakterije, pa je najpogostejši patogen S. pyogenes, ki je vedno občutljiv za penicillin in se zdravi samo z amoksicilinom ali s penicilinom.
PK/PD analyses predict that the 2:1 Augmentin oral formulation (250/125mg) TID would achieve maximum eradication against S. pneumoniae strains with amoxicillin or amoxicillin/clavulanic acid MICs of ≤1 μg/mL whereas the 4:1 ratio (500/125mg) TID would be effective against strains with MICs of ≤ 2μg/mL. 
trikrat dnevno dosegla največjo eradikacijo sevov S. pneumoniae, ki imajo MIC za amoksicilin ali kombinacijo amoksicilin/klavulanska kislina ≤1 μg/mL, razmerje 4:1 (500/125mg) trikrat dnevno pa bi bilo učinkovito proti sevom z vrednostmi MIC ≤2 μg/mL.
The CHMP noted the detailed literature search and analyses of available data carried out by the MAH, and agreed with the text on oral anticoagulants but requested the MAH to include a statement on the interaction with methotrexate. 
Odbor se je strinjal z besedilom o peroralnih antikoagulacijskih zdravilih, vendar je od imetnikov dovoljenj za promet z zdravilom zahteval izjavo o interakciji z metotreksatom.
• Acute otitis media • Community acquired pneumonia. 
• akutno vnetje srednjega ušesa • izvenbolnišnično pridobljena pljučnica.
In summary, the following harmonised wording for inclusion in the harmonised SPCs was agreed and adopted by the CHMP: 
CHMP je potrdil in sprejel naslednje usklajeno besedilo, ki se vključi v usklajene povzetke glavnih značilnosti zdravila:
The indication in community acquired pneumonia (CAP) is supported but the indications for ABS and AECB required further discussion. 
Indikacija izvenbolnišnično pridobljene pljučnice je podprta, vendar indikaciji akutni bakterijski sinusitis in akutno poslabšanje kroničnega bronhitisa zahtevata dodatno razpravo.
A BID regimen would therefore probably not attain the required PK/PD target required to eradicate pathogens with higher MICs. 
Režim dvakrat dnevno zato verjetno ne bo dosegel ciljne farmakokinetike/farmakodinamike, ki sta potrebni za eradikacijo patogenov z vrednostjo MIC. Patogeni z višjimi vrednostmi MIC so nagnjeni k večji pogostnosti pri bolnikih z resnejšimi okužbami, zato lahko i.v.
• Acute otitis media 
• akutno vnetje srednjega ušesa
A harmonised wording was agreed by the CHMP for inclusion in the harmonised SPCs. 
CHMP se je strinjal z usklajenim besedilom, ki se vključi v usklajene povzetke glavnih značilnosti zdravila.
THERAPEUTIC INDICATION FOR AUGMENTIN 8:1 RATIO (ORAL) 
TERAPEVTSKA INDIKACIJA ZA ZDRAVILO AUGMENTIN Z RAZMERJEM 8:1 (PERORALNO)
In line with the previous discussion on 12-hour dosing, the CHMP changed the posology for the 10:1 IV ratio accordingly. 
razmerja 10:1 skladno s predhodno razpravo o 12-urnem odmerjanju.
THERAPEUTIC INDICATIONS FOR AUGMENTIN 14:1 RATIO (ORAL - ES) 
TERAPEVTSKE INDIKACIJE ZA ZDRAVILO AUGMENTIN Z RAZMERJEM 14:1 (PERORALNO - ES)
The CHMP generally agreed with the MAH conclusion, but further discussed the indications in LRTIs, URTIs, UTIs, gynaecological infections, SSTIs, bone and joint infections and the prophylaxis of surgical infections and agreed and adopted the following harmonised wording for inclusion in the harmonised SPCs: 
CHMP se je na splošno strinjal z zaključki imetnikov dovoljenj za promet z zdravilom, vendar je dodatno razpravljal o indikacijah okužbe spodnjih dihal, okužbe zgornjih dihal, okužbe sečil, ginekološke okužbe, okužbe kože in mehkih tkiv, okužbe kosti in sklepov ter profilaksa kirurških okužb.
THERAPEUTIC INDICATIONS FOR AUGMENTIN 7:1 RATIO (ORAL) 
TERAPEVTSKE INDIKACIJE ZA ZDRAVILO AUGMENTIN Z RAZMERJEM 7:1 (PERORALNO)
The CHMP agreed with the MAH proposal to include wording in the SPC of several Augmentin formulations regarding the possibility to switch from IV to oral treatment for a number of indications but was of the opinion that switch from IV to oral therapy is not restricted to particular indications and should be an option for all indications. 
CHMP se je strinjal s predlogom imetnikov dovoljenj za promet z zdravilom, da se v povzetek glavnih značilnosti več formulacij zdravila Augmentin vključi besedilo o možnosti prehoda iz i.v.
In addition, IV-to-oral switch therapy for Augmentin 14:1 (ES) and 16:1 (SR) was considered a valuable option for switch from IV treatment in infections where PRSP are, or are thought to be the causative agent and where oral continuation of Augmentin treatment is necessary. 
na peroralno zdravljenje za zdravili Augmentin 14:1 (ES) in 16:1 (SR) štel za dobro možnost prehoda z i.v.
THERAPEUTIC INDICATIONS FOR AUGMENTIN 2:1 RATIO (ORAL) 
TERAPEVTSKE INDIKACIJE ZA ZDRAVILO AUGMENTIN Z RAZMERJEM 2:1 (PERORALNO)